Halofuginone Treatment reduces interleukin-17A and ameliorates features of chronic lung allograft dysfunction in a mouse orthotopic lung transplant model

Background Increasing evidence suggests that interleukin (IL)-17A plays an important role in chronic lung allograft dysfunction (CLAD), characterized by airway and lung parenchymal fibrosis, after lung transplantation. Halofuginone is a plant derivative that has been shown to inhibit Th17 differenti...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The Journal of heart and lung transplantation 2016-04, Vol.35 (4), p.518-527
Hauptverfasser:	Oishi, Hisashi, MD, PhD, Martinu, Tereza, MD, Sato, Masaaki, MD, PhD, Matsuda, Yasushi, MD, PhD, Hirayama, Shin, MD, PhD, Juvet, Stephen C., MD, PhD, Guan, Zehong, Saito, Tomohito, MD, PhD, Cypel, Marcelo, MD, MSc, Hwang, David M., MD, PhD, Keller, Tracy L., PhD, Whitman, Malcolm R., PhD, Liu, Mingyao, MD, MSc, Keshavjee, Shaf, MD, MSc
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Chronic Disease chronic lung allograft dysfunction Disease Models, Animal Graft Rejection - drug therapy Graft Rejection - immunology Graft Rejection - pathology halofuginone IL-17 Interleukin-17 - metabolism Lung Transplantation Male Mice Mice, Inbred C57BL obliterative bronchiolitis Piperidines - pharmacology Protein Synthesis Inhibitors - pharmacology Quinazolinones - pharmacology restrictive allograft syndrome Surgery Th17 Cells - immunology Transplantation, Homologous
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!